News

Enrolling 1,000 Patients

Written by Yourway | May 21, 2020

Clinical testing has begun on Gilead’s antiviral drug remdesivir coupled with baricitinib, an anti-inflammatory medicine. The enrollment of more than 1,000 participants is ongoing. In addition to supporting clinical trials, Yourway can also provide all ancillary materials needed during a trial, no matter how large the scale.